ARB 1467

Drug Profile

ARB 1467

Alternative Names: ARB 1468; ARB-001467; ARB-1467; TKM HBV

Latest Information Update: 10 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Protiva Biotherapeutics
  • Developer Arbutus Biopharma
  • Class Antivirals; Small interfering RNA
  • Mechanism of Action RNA interference; Surface antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatitis B

Most Recent Events

  • 02 Nov 2017 Arbutus plans a phase II triple combination, multi-dose trial to evaluate ARB 1467, tenofovir, and pegylated interferon for Hepatitis B in fourth quarter of 2017
  • 03 Oct 2017 Interim pharmacokinetics data from a phase IIa trial in Hepatitis B released by Arbutus Biopharma
  • 25 Sep 2017 Efficacy and adverse events data from the fourth cohort of a phase II trial in Hepatitis B released by Arbutus
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top